👍

gold 

How does an investor safeguard her portfolio and goals from high inflation? $Tesla Motors(TSLA)$ $NASDAQ-100 Index ETF(QQQ)$ $S&P500 ETF(SPY)$ $S&P 500(.SPX)$  Essentially, there are two broad ways. Outpacing inflation is about positioning your portfolio to grow bigger over a while and deliver returns that exceed the inflation rate. If your goal is to build a corpus for future spending and the goal is at least ten years away, then this strategy works. Hedge against inflation broadly focuses on protecting your near-term consumption from rising inflation. It is applicable especially if you are nea

Many companies such as Pfizer and Amgen are developing weight loss drugs, as Barclays has predicted a $100 billion global market for obesity drugs by 2030. Females of ages 18-34 are the target customers of weight loss products. In a separate note,  The sugar industry is an example of a weight-losing industry. Weight-gaining industries are industries whose raw materials are lighter but finished products are heavier and bulky. They tend to locate near markets.

I try me so happy for this

$Novo-Nordisk A/S(NVO)$ Their dividends has historically grown at 10% a year. Holding NVO you will beat inflation by a fine margin. Regulations is their biggest risk for me, so i’m not all in but it has become a sizeable position in my portfolio the last couple of months. The other risk is that they are not as diversified as for instance LLY.I do believe long term it should be pretty safe . The trend the last 100 years is that people are getting fatter and fatter. Even if Denmark increases their tax rates or whatever they can to harvest more government money from NVO, i don’t believe it will do much long term. Maybe cause short term volatility, but nothing im too worried about. I sleep well with NVO in my portfolio

$Novo-Nordisk A/S(NVO)$ I've been eyeing Novo Nordisk ($NVO) recently, and I'm intrigued by its position in the pharmaceutical sector, especially given its focus on diabetes and obesity treatments. As we all know, these are significant healthcare issues that aren't going away anytime soon.Novo Nordisk has a long history of stable growth and has shown resilience during economic downturns. However, competition is fierce in the pharma sector, and it's not uncommon for market leaders to lose their position swiftly.NVO has a history of providing decent dividends. Do you think this is sustainable in the long term?Image

1. Pharma stocks $Regeneron Pharmaceuticals(REGN)$ and $Vertex Pharmaceuticals(VRTX)$ hit new high of $853.97 and $374.45 respectively. $Regeneron Pharmaceuticals(REGN)$ three core value drivers are its eye disease drug Eylea (now available in a high-dose form), immunology drug Dupixent, and anti-cancer therapy Libtayo. FDA approved its high-dose Eylea in August.  $Vertex Pharmaceuticals(VRTX)$ is striving to develop treatments for APOL1-mediated kidney disease, non-opioid pain medications, rare blood disorders, and diabetes. 2. Insurance stocks $Arch Capital(ACG

LLY NVO want to become star contributor

Yam and hammed. Beautiful brave one'd

I’m hoping for a pause, but seems there’s still a chance for one last rate hike this year…

Not a true believer of the Weight Loss industry. The whole model is based upon you loosing weight, and then putting it on again gradually, just in time to go back to them after Xmas and pay more just too try too loose weight again. So yes it's lucrative, and ideal for good returns because customers always comes back, but it also show some fundamental flaws of society where it all becomes a quick fix to get what you want. Did you know that out of a hundred people loosing weight with Weight Watchers, according to the news 97 will put the weight on again ! So I don't think the Soda pop industry will go under anytime soon.

Hi there ... Which is the best company to start investing with?

Novo Nordisk: Super Focused Pharma Company For The Long Run $Novo-Nordisk A/S(NVO)$  Novo Nordisk is a high-quality pharmaceutical company with a unique ownership structure, controlled by a charitable foundation. The company specializes in diabetes and obesity treatments, with a focus on insulin and GLP-1 analogues. Despite a temporary slowdown in recent years, Novo Nordisk is back on track for strong growth and has the potential for further diversification in the future. Novo Nordisk is a 100-year-old company that until recently almost exclusively focused on diabetes treatment. As such, the company has almost no direct peers. The closest peer is Eli Lilly (LLY) which generates about half of its business from the diabetes area. Until 2019, Nov